Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fluocinolone acetonide intravitreal implant - Bausch and Lomb/EyePoint Pharmaceuticals

Drug Profile

Fluocinolone acetonide intravitreal implant - Bausch and Lomb/EyePoint Pharmaceuticals

Alternative Names: Fluocinolone acetonide Envision TD implant; Retisert

Latest Information Update: 18 Mar 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator pSivida Inc
  • Developer Bausch & Lomb
  • Class Anti-inflammatories; Antipruritics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Pregnadienes; Small molecules; Vasoconstrictors
  • Mechanism of Action Glucocorticoid receptor agonists; Nitric oxide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveitis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Uveitis
  • Discontinued Age-related macular degeneration; Choroidal neovascularisation; Diabetic macular oedema

Most Recent Events

  • 11 Sep 2017 Fluocinolone acetonide intravitreal implant is licensed to Bausch and Lomb
  • 05 Aug 2013 Bausch & Lomb has been acquired by Valeant Pharmaceuticals International
  • 27 Oct 2007 Bausch and Lomb has been acquired by Warburg Pincus
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top